Detremin 800 IE/ dråpe Norge - norsk - Statens legemiddelverk

detremin 800 ie/ dråpe

renapharma ab - kolekalsiferol - dråper, oppløsning - 800 ie/ dråpe

Vigantol 20000 IE/ ml Norge - norsk - Statens legemiddelverk

vigantol 20000 ie/ ml

2care4 aps - kolekalsiferol - dråper, oppløsning - 20000 ie/ ml

Mavenclad 10 mg Norge - norsk - Statens legemiddelverk

mavenclad 10 mg

orifarm as - kladribin - tablett - 10 mg

Prialt Den europeiske union - norsk - EMA (European Medicines Agency)

prialt

esteve pharmaceuticals gmbh - ziconotid - injections, spinal; pain - analgetika - ziconotid er indisert for behandling av alvorlig kronisk smerte hos pasienter som krever intratekal (it) analgesi.

Midazolam Panpharma 1 mg/ ml Norge - norsk - Statens legemiddelverk

midazolam panpharma 1 mg/ ml

panpharma sa - midazolam - injeksjonsvæske, oppløsning - 1 mg/ ml

Midazolam Panpharma 5 mg/ ml Norge - norsk - Statens legemiddelverk

midazolam panpharma 5 mg/ ml

panpharma sa - midazolam - injeksjonsvæske, oppløsning - 5 mg/ ml

Thiotepa Riemser Den europeiske union - norsk - EMA (European Medicines Agency)

thiotepa riemser

esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastiske midler - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Temozolomide Teva Den europeiske union - norsk - EMA (European Medicines Agency)

temozolomide teva

teva b.v.  - temozolomid - glioma; glioblastoma - antineoplastiske midler - for behandling av voksne pasienter med nylig diagnostisert glioblastom multiforme samtidig med strålebehandling (rt) og deretter som monoterapibehandling. for behandling av barn fra en alder av tre år, unge og voksne pasienter med ondartet glioma, slik som glioblastoma multiforme eller anaplastic astrocytom, viser tilbakefall eller progresjon etter standard terapi.

Mavenclad Den europeiske union - norsk - EMA (European Medicines Agency)

mavenclad

merck europe b.v. - cladribine - multippel sklerose - immunsuppressive - behandling av voksne pasienter med svært aktiv recidiverende multippel sklerose (ms) som definert av kliniske eller imagingfunksjoner.

Phelinun Den europeiske union - norsk - EMA (European Medicines Agency)

phelinun

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastiske midler - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.